Article Text

other Versions

PDF
Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility
  1. Y Kawaguchi (y-kawa{at}ior.twmu.ac.jp)
  1. Tokyo Women's Medical University, Japan
    1. Y Nakamura (y-nakamura{at}md.tsukuba.ac.jp)
    1. University of Tsukuba, Japan
      1. I Matsumoto (ismatsu{at}md.tsukuba.ac.jp)
      1. University of Tsukuba, Japan
        1. E Nishimagi (enishimagi{at}ybb.ne.jp)
        1. Tokyo Women's Medical University, Japan
          1. T Satoh (takashis{at}sc.itc.keio.ac.jp)
          1. Keio University, Japan
            1. M Kuwana (kuwanam{at}sc.itc.keio.ac.jp)
            1. Keio University, Japan
              1. T Sumida (tsumida{at}md.tsukuba.ac.jp)
              1. University of Tsukuba, Japan
                1. M Hara (mhara{at}ior.twmu.ac.jp)
                1. Tokyo Women's Medical University, Japan

                  Abstract

                  Objective: Patients with systemic sclerosis (SSc) complicated by severe gastrointestinal tract (GIT) dysmotility at an early stage are difficult to treat and mortality is high. To clarify the pathogenesis of GIT involvement, we investigated the occurrence of autoantibody for muscarinic-3 acetylcholine receptor in patients with SSc.

                  Methods: Fourteen patients with severe GIT involvement (malabsorption syndrome and/or pseudo-obstruction) within 2 years of SSc onset (Group 1) were enrolled in the present study. Sixty-two patients with SSc without severe GIT involvement within 2 years of onset (Group 2) were also recruited, along with 70 healthy control subjects. Using an established enzyme immunoassay (EIA) system detecting autoantibody against the second loop domain of muscarinic-3 acetylcholine receptor (M3R), we examined the presence of an anti-M3R antibody in SSc patients.

                  Results: The mean optical density (OD) titers of Group 1 were significantly higher than those of Group 2 (0.65 ± 0.58 versus 0.066 ± 0.13, P < 0.001). The positivity of anti-M3R antibody was significantly higher in Group 1 than in Group 2 (9/14 versus 3/62, P = 2.5 × 10−6 by Fisher’s exact test). The cutoff OD was calculated from the EIA reaction of the 70 healthy controls (the mean value + two standard deviation was 0.295).

                  Conclusion: Our findings indicated that anti-M3R antibody very frequently appears in patients with SSc that is accompanied by severe GIT involvement, suggesting that M3R-mediated enteric cholinergic neurotransmission may provide a pathogenic mechanism for the GIT dysmotility in SSc.

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                  Linked Articles